Edgar Filing: Intellicell Biosciences, Inc. - Form NT 10-Q

Intellicell Biosciences, Inc. Form NT 10-Q May 15, 2014

Full Name of Registrant

Former Name if Applicable

460 Park Avenue, 17th Floor

New York, New York 10022 City, State and Zip Code

Address of Principal Executive Office (Street and Number)

UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0058
Expires: August 31, 2015
Estimated average burden hours

per response ... 2.50

FORM 12b-25 SEC FILE NUMBER 000-54729

NOTIFICATION OF LATE FILING

CUSIP NUMBER

(Check one):	[] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR	
	For Period Ended:	March 31, 2014
	[] Transition Report on Form 10-K	
	[] Transition Report on Form 20-F	
	[] Transition Report on Form 11-K	
	[] Transition Report on Form 10-Q	
	[] Transition Report on Form N-SA	R
	For the Transition Period Ended:	
	d Instruction (on back page) Before Pre in this form shall be construed to imply information contain	y that the Commission has verified any
If the notifi	cation relates to a portion of the filing of	checked above, identify the Item(s) to which the notification relates:
PART I —	REGISTRANT INFORMATION	
Intellicell E	Biosciences, Inc.	

Edgar Filing: Intellicell Biosciences, Inc. - Form NT 10-Q

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- [X](a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- [X](b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- [] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Registrant was not able to obtain all information prior to filing date and management could not complete the required financial statements and Management's Discussion and Analysis of such financial statements by May 15, 2014.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Steven A. Victor (646) 576-8700 (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes [X] No []

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes [] No [X]

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Edgar Filing: Intellicell Biosciences, Inc. - Form NT 10-Q

INTELLICELL BIOSCIENCES, INC. (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2014 By: /s/ Steven A. Victor

Name: Steven A. Victor Title: Chief Executive Officer

3